Okita K - Search Results

1

Association between severity of type A hepatitis and nucleotide variations in the 5' non-translated region of hepatitis A virus RNA: strains from fulminant hepatitis have fewer nucleotide substitutions.

Fujiwara K, Yokosuka O, Ehata T, Saisho H, Saotome N, Suzuki K, Okita K, Kiyosawa K, Omata M. Fujiwara K, et al. Among authors: okita k. Gut. 2002 Jul;51(1):82-8. doi: 10.1136/gut.51.1.82. Gut. 2002. PMID: 12077097 Free PMC article.

2

A multi-centre double-blind controlled trial of glucagon and insulin therapy for severe acute hepatitis.

Oka H, Fujiwara K, Okita K, Ishii H, Sakuma A. Oka H, et al. Among authors: okita k. Gastroenterol Jpn. 1989 Jun;24(3):332-6. doi: 10.1007/BF02774333. Gastroenterol Jpn. 1989. PMID: 2663609 Clinical Trial.

3

Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.

Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, Kiyosawa K, Okita K. Kasahara A, et al. Among authors: okita k. J Viral Hepat. 2000 Sep;7(5):343-51. doi: 10.1046/j.1365-2893.2000.00250.x. J Viral Hepat. 2000. PMID: 10971822 Clinical Trial.

4

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K. Kasahara A, et al. Among authors: okita k. Hepatology. 1998 May;27(5):1394-402. doi: 10.1002/hep.510270529. Hepatology. 1998. PMID: 9581697 Clinical Trial.

5

Antithrombin III concentrate in the treatment of fulminant hepatic failure.

Fujiwara K, Okita K, Akamatsu K, Abe H, Tameda Y, Sakai T, Inoue N, Kanai K, Aoki N, Oka H. Fujiwara K, et al. Among authors: okita k. Gastroenterol Jpn. 1988 Aug;23(4):423-7. doi: 10.1007/BF02779211. Gastroenterol Jpn. 1988. PMID: 3181667

6

Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver.

Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K. Okuda M, et al. Among authors: okita k. Hepatology. 1999 Jan;29(1):217-22. doi: 10.1002/hep.510290117. Hepatology. 1999. PMID: 9862869

7

Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan.

Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M. Orito E, et al. Among authors: okita k. Hepatology. 2001 Sep;34(3):590-4. doi: 10.1053/jhep.2001.27221. Hepatology. 2001. PMID: 11526547

8

Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy.

Hino K, Okuda M, Konishi T, Ishiko H, Okita K. Hino K, et al. Among authors: okita k. Dig Dis Sci. 1995 Jan;40(1):14-20. doi: 10.1007/BF02063935. Dig Dis Sci. 1995. PMID: 7821101

9

Differences in hypervariable region 1 quasispecies of hepatitis C virus between human serum and peripheral blood mononuclear cells.

Fujii K, Hino K, Okazaki M, Okuda M, Kondoh S, Okita K. Fujii K, et al. Among authors: okita k. Biochem Biophys Res Commun. 1996 Aug 23;225(3):771-6. doi: 10.1006/bbrc.1996.1249. Biochem Biophys Res Commun. 1996. PMID: 8780688

10

Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.

Hino K, Yamaguchi Y, Fujiwara D, Katoh Y, Korenaga M, Okazaki M, Okuda M, Okita K. Hino K, et al. Among authors: okita k. J Viral Hepat. 2000 Jan;7(1):36-42. doi: 10.1046/j.1365-2893.2000.00196.x. J Viral Hepat. 2000. PMID: 10718941 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

939 results

Search Page